• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oncology Pharma Inc (OP:ONPH)

0.0051 UNCHANGED
Streaming Delayed Price Updated: 11:17 AM EST, Feb 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 319
Open 0.0051
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0051
Today's Range 0.0051 - 0.0051
52wk Range 0.0001 - 0.0100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
World Awaits Bankman-Fried Sentence, Drug Stock Pump-And-Dump, Penny Stock Fraud: Financial Crimes Weekly ↗
March 23, 2024
Prosecutors push for harshest punishment for Sam Bankman-Fried, convicted on fraud charges in FTX collapse. Defense seeks leniency. 
Via Benzinga
Topics Fraud Lawsuit
News headline image
Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
July 12, 2022
SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is furthering progress in discussions with investors and developing the... 
From Oncology Pharma Inc.
Via AccessWire

Performance

YTD
+27.5%
+27.5%
1 Month
-7.3%
-7.3%
3 Month
-25.0%
-25.0%
6 Month
+2450.0%
+2450.0%
1 Year
+5000.0%
+5000.0%

More News

Read More
News headline image
Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
June 29, 2022
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development
June 08, 2022
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development
May 09, 2022
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer
April 13, 2022
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Reports on Progress with Ribera Solutions
March 02, 2022
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Releases Further Feasibility Studies, Data and Capacities
February 23, 2022
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Expands on Feasibility Studies and Data
February 17, 2022
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
February 14, 2022
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Gives Update on Technology, Formulation and Data Creation
February 08, 2022
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma's New Year Update
January 10, 2022
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Meeting Towards Future Developments
December 17, 2021
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Year End Review and Outlook
December 09, 2021
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma Research and Vision
November 30, 2021
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate
November 08, 2021
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress
October 27, 2021
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
October 15, 2021
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Oncology Pharma, Inc. Update on PCAOB Audit Selection Process and License Agreement
October 12, 2021
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product
September 13, 2021
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives
August 23, 2021
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
August 19, 2021
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP
July 20, 2021
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase
June 30, 2021
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties
June 15, 2021
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property

Frequently Asked Questions

Is Oncology Pharma Inc publicly traded?
Yes, Oncology Pharma Inc is publicly traded.
What exchange does Oncology Pharma Inc trade on?
Oncology Pharma Inc trades on the OTC Traded
What is the ticker symbol for Oncology Pharma Inc?
The ticker symbol for Oncology Pharma Inc is ONPH on the OTC Traded
What is the current price of Oncology Pharma Inc?
The current price of Oncology Pharma Inc is 0.0051
When was Oncology Pharma Inc last traded?
The last trade of Oncology Pharma Inc was at 02/26/26 11:17 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap